Is There an Alternative — to Chemotherapy?

Targeted therapy blocks the specific molecular signal your cancer needs to grow. Its side effects differ from chemotherapy — skin changes, diarrhoea and liver effects are common depending on the drug — but are not automatically fewer or milder. It only works when your tumour carries the specific mutation the drug targets. Biomarker testing is what confirms whether that applies to you, which is why testing comes before any treatment decision.

For hormone-receptor-positive breast cancer, hormone therapy is frequently the primary treatment — particularly at early stages — and ASCO and ESMO guidance confirms that many patients in this group do not need chemotherapy. Prostate cancer is similarly managed with hormone-blocking therapy across several stages. The deciding test is hormone receptor status from your biopsy. If you have not been told that result, it is the first thing to ask at your next appointment.

Yes. Some cancers — certain lymphomas, many sarcomas, and lung cancers without targetable mutations among them — do not have an equally effective chemo-free alternative at present. For these, chemotherapy is the recommended treatment because the evidence supports it and no equivalent alternative exists for that specific tumour. Asking about alternatives is not about avoiding chemotherapy at any cost — it is about confirming you are not receiving it when a better-matched treatment exists.

The tests that matter depend on your cancer type. For lung cancer, ask about EGFR, ALK, ROS1 and PD-L1. For breast cancer, ask about hormone receptor status (ER and PR) and HER2. For colorectal cancer, ask about KRAS, NRAS and microsatellite instability. Your oncologist knows which tests apply — the reason to ask is to confirm that testing has been done and to understand what the results mean for your treatment options.

The most useful framing is not 'I refuse chemotherapy' but 'Is there an alternative the evidence supports for my specific tumour?' That is a reasonable question, and a clear answer is reasonable to expect. If an alternative exists, ask what it is intended to achieve. If there is not one, ask why chemotherapy is the right approach for your tumour. A second opinion from another oncologist is always available if you remain uncertain after that conversation.

For tumours with high PD-L1 expression or microsatellite instability, immunotherapy can replace or be given alongside chemotherapy, and for some cancers it is now the preferred first treatment per NCCN guidance. It does not suit most patients — eligibility depends on biomarker testing of the tumour tissue, not the cancer type alone. Immune-related side effects, which can affect the gut, liver, lungs and hormone-producing glands, require monitoring throughout and after treatment.